Similar Papers

Paper Title
Journal
Date
Author
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Jihong Liu ... Li Wang
Journal of Clinical Oncology | VOL. 41
Jihong Liu, et. al.Jihong Liu ... Li Wang
01 Jun 2023
Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)
Bradley Monk ... Domenica Lorusso
Gynecologic Oncology | VOL. 166
Bradley Monk, et. al.Bradley Monk ... Domenica Lorusso
01 Aug 2022
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
Xiaohua Wu ... Michelle Xia
The Lancet | VOL. 404
Xiaohua Wu, et. al.Xiaohua Wu ... Michelle Xia
01 Oct 2024
First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
Jianying Lei ... Na Li
Value in Health | VOL. 27
Jianying Lei, et. al.Jianying Lei ... Na Li
02 Aug 2024
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Comments on The Study of Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma
Yue-Can Zeng ... Yi Wang
Annals of Oncology | VOL. -
Yue-Can Zeng, et. al.Yue-Can Zeng ... Yi Wang
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.